US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.
There wasn't a deluge of NMEs of approved in April, but the last two to get through benefited from the umbrella of well-crafted safety labeling. • Source: Shutterstock
The US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.
